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 The most common intervention used by doctors is to prescribe drugs. 
 Related to this is the problem of poor medication adherence.
 Motivational Interviewing, is an interview style designed to promote 
behavioural changes.
 Motivational Interviewing is a patient-centered methods that can be used to 
improve medication adherence en primary care.
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Objective: To evaluate the effectiveness of motivational interviewing (MI) in improving 
medication adherence in older patients being treated by polypharmacy. 
Methods: Cluster randomized clinical trial in 16 primary care centers with 27 health 
care providers and 154 patients. Thirty-two health care providers were assigned to an 
experimental (EG) or control group (CG). Interventions: MI training program and 
review of patient treatments. Providers in the EG carried out MI, whereas those in the 
CG used an “advice approach”. Three follow-up visits were completed, at 15 days and 
at 3 and 6[0] months. Medication adherence in both groups was compared (p<0.05).
Results: Patients recruited: 70/84 (EG/CG). Mean age: 76 years; female: 68.8%. The 
proportion of subjects changing to adherence was 7.6% higher in the EG (p<0.001). 
Therapeutic adherence was higher for patients in the EG (OR=2.84), women (OR=0.24) 
and those with high educational levels (OR=3.93). 
Conclusion: A face-to-face motivational approach in primary care helps elderly 
patients with chronic diseases who are being treated by polypharmacy to achieve an
improved level of treatment adherence than traditional strategies of providing 
information and advice.
Practice Implications: MI is a patient-centered approach that can be used to improve 
medication adherence in primary care.
Trial Registration
This trial is registered at ClinicalTrials.gov (NCT01291966).
Keywords
Medication adherence, Communication, Geriatrics, General practice/family medicine, 
Treatment/intervention research, Patient involvement (empowerment, self-
management)













The most common intervention used by physicians is to prescribe medication. 
However, a problem often related to this intervention is that of poor medication 
adherence (MA). Medication adherence is defined as the patient's decision to accept 
and follow the instructions for taking the prescribed medication [1,2]. In the setting of 
chronic medical conditions such as hypertension and hypercholesterolemia, poor MA 
leads to worse medical treatment outcomes, higher hospitalization rates, and 
increased health care costs [3,4]. Because of this, adherence has been called “the key 
mediator between medical practice and patient outcomes” [5]. 
In people over 65 years of age, the prevalence of polypharmacy has been estimated at 
around 40% [6,7], and poor MA can have a negative he lth impact in this population 
group. Therefore, this subpopulation is considered a target for optimization of MA 
policies [8]. Different kinds of interventions have been tested to improve patient 
adherence, ranging from simple adjustments in the medication regimen to complex 
multidisciplinary interventions [9–13]. However, interventions to improve medication 
compliance for chronic conditions appear to be less effective and a combination of 
multifaceted interventions is considered the most effective strategy [14]. Given a lack 
of confidence in the prescriber and treatment, and concerns surrounding patient 
knowledge about prescribed medication [15], any strategy to improve medication 
adherence must include clear and tailored information [15,16]. Furthermore, most 
elderly patients frequently suffer from asymptomatic chronic diseases and many of 
them do not consider medication necessary, which frequently leads them to stop 
taking their medicine [17]. In these cases, communication strategies designed to 












promote patient self-empowerment and behavioral changes are particularly suitable 
[18].
Motivational Interviewing (MI) is an interview style designed to promote behavioral 
changes, and is defined as "a set of targeted communication skills to motivate patients 
to change their own behaviors in the interest of their health" [19]. In certain 
circumstances, MI has proven more effective than other strategies, such as the 
traditional informative strategy [20], and has been shown to be as equally effective as 
cognitive behavioral therapy, but with less time cost [21, 22]. However, evidence of 
the effectiveness of MI in these areas remains scarce and further studies are required 
[23, 24].
The objective of this study was to determine whether a face-to-face communicative 
strategy based on MI, used by health practitioners (family physicians and nurses) in a 
primary care setting and aimed at patients over 65 years old with a chronic disease 
who are being treated by polypharmacy and who have poor MA, can achieve better 
results than the usual approach based on an informative model of providing education 
and advice. 
2 Methods
2.1 Study Design 
This two-arm trial, with experimental group (EG) and control group (CG), was 
conducted using a cluster randomized design, where two subpopulation levels were 
considered: (1) health professionals and (2) patients. Figure 1 shows the CONSORT 
flow diagram with the cluster design features (25). The study took 18 months to 












complete, the patient recruitment period was from April 2009 to January 2010, and 
the follow-up period was 6 months.
2.2 Setting and Subjects 
The study was conducted in 16 health centers in Córdoba Province, Spain. One 
hundred health care providers (nurses and physicians from our Department of Family 
Medicine mailing list) were invited to participate, and 32 accepted. Allocation was 
based on clusters, and was stratified by profession (nurse or physician). We 
performed blinded randomization to one of the two study arms (C4-Study Design
Pack; Glaxo S.A.). 
Patients older than 65 who had chronic disease and were being treated by
polypharmacy (taking 5 or more medicines or 12 or more daily doses for a period of no 
less than 6 months) [26], and who had a high probability for non-adherence to the 
prescribed treatment, were selected (consecutive sample) by health care providers. An
informed consent form was signed when each patient agreed to participate. Poor MA 
was assessed using the Haynes–Sackett [1] survey and the Morisky–Green test [27]. 
The former asks one question: “Most patients have difficulty taking all of their pills. 
Do you have any problems taking yours?” Because of its high specificity, this test is 
recommended in clinical practice as a first screening method to assess medication 
compliance [28]. The Morisky–Green scale comprises four yes/no questions: “Do you 
ever forget to take your medicines?”; “Are you careless at times about taking your 
medicine?”; “When you feel better, do you sometimes stop taking your medicine?”;
and “Sometimes, if you feel worse when you take your medicine, do you stop taking 
it?” MA was considered to be poor when the patient answered affirmatively to the 












Haynes–Sackett question and answered inconsistently to at least one of the four 
Morisky–Green test questions.
Patients who were excluded from the study were those with serious psychiatric and 
neurological diseases, those who had difficulties coping with basic daily activities 
(Barthel Index below 60) [29], those who had cognitive impairment (Pfeiffer’s test)[30], 
those admitted to hospital at least twice in the last year and patients under a carer’s 
supervision.
2.3 Interventions
Before intervention, health care providers in both groups attended a 15-hour
workshop on patient safety and MA. Then providers from the EG attended an 
additional 20-hour-long workshop on MI. This training was conducted by two of the 
authors (JAFG; JMPR), who are both family physicians with experience in teaching 
physician-patient communication skills. The workshop was based on diverse 
interactive methodologies (trigger videos, discussions, role-playing alternative 
strategies, feedback and rehearsal). 
To assess the effectiveness of specific training for acquisition of motivational skills, 
participants in both groups were videotaped in a simulated encounter, and two 
evaluators independently scored these interviews using the CICAA and EVEM tools. 
The CICAA is a rating scale designed to evaluate patient-centered generic skills [31],
and the EVEM evaluates specific MI skills [32]. A previously published inter-rater 
reliability assessment was carried out, which produced a good reproducibility index 
(Cohen’s kappa > 0.4 in all items, and intraclass correlation coefficient > 0.90). CICAA 
scale results were as follows: rater A=30.57 points (EG) versus 16.56 points (CG), 
p=0.003; rater B=29.7 (EG) versus 17.7 (CG), p=0.04. EVEM scale results were as 












follows: rater A=21.1 (EG) versus 12.1 (CG), p=0.022; rater B=20 (EG) versus 12.6 (CG), 
p=0.01.  
Time between the training program and patient recruitment and intervention was 
about two weeks. Interventions in both groups included: 1) initial assessment of the 
status of each patient regarding medication; 2) detection of critical incidents and 
possible medication errors; 3) providing information (e.g., an informative pamphlet)
that effectively describes prescribed medications (usefulness, indications, side effects, 
dosage, active formula, and other information) [33]; 4) developing a customized action 
plan; and 5) proposal for implementation of activities included in the plan. The latter 
two interventions were implemented using different approaches in each group: the CG 
based the interventions on informative, persuasive and advice strategies, while
motivational strategies were used in the EG (see below).
2.4 Main Features of Motivational Interviewing
MI is a counselling method that involves enhancing a patient's motivation to change 
behavior by means of four guiding principles, represented by the acronym RULE: 
Resist the righting reflex; Understand the patient’s own motivations; Listen with 
empathy; and Empower the patient. Conducting MI does not only involve applying a 
series of techniques, but also aims to create a spirit of collaboration and evoke a 
sense of personal resources, while respecting the patient’s autonomy and personal 
freedom of choice [19]. 
Examination and resolution of ambivalence regarding treatment adherence is the main 
focus of this non-directive counselling, and the EG providers were trained to be 
intentionally directive in pursuing this goal. Intervention in the EG was more 












supportive than coercive and argumentative, with an overall goal to increase the 
patient’s intrinsic motivation so that change could arise from within rather than 
being imposed from without. The EG providers followed these steps: 1) Assessment 
of ambivalence; 2) Exploration of patients’ ideas and concerns about their lack of 
adherence; 3) Application of specific interviewing skills for re-framing and promoting 
self-efficacy (using empathy, developing discrepancies, avoiding arguments, 
confronting barriers and problems, supporting the patient, and others). The CG 
providers used an informative approach reinforced by persuasive strategies and 
personal advice.
2.5 Measurements and Outcomes 
Scheduled visits were as follows: V0 or baseline visit (intake and initial assessment); V1 
or second visit (at 15 to 20 days in patient's home); V2 or third visit (at 3 months in a 
health care setting); and V3 or final visit (at 6 months in patient's home). Office visits 
were about 15 minutes’ duration, whereas home visits time were between 45 and 60 
minutes, with no differences between the EG and CG. 
Independent variables measured were: health center (urban or rural), provider (doctor
or nurse), patient data (age, gender, marital status, educational level, occupation), 
chronic diseases, quality of life related to health, pharmacotherapeutic data, electronic 
prescription, treatment data (attendance at health center and hospital). Diseases were 
coded according to ICD-9 [34] classification, whereas drugs were classified by the ATC
coding system [35]. Quality of life was measured by applying the COOP-WONCA charts 
[36]. 
Dependent variables measured were as follows. The primary outcome was MA, 
measured as average adherence percentage and calculated using the following 














formula: (Number of tablets presumably consumed/Number of tablets that should be 
consumed) × 100. An adherent patient was defined as having an average adherence 
>80% and <110% [1, 36, 37]. The method of MA assessment was similar at baseline 
and during the two follow-up home visits (V1 and V3), during which a review and 
medication count were taken. 
2.6 Sample Size  
This study belongs to a wider study, the ATEM-AP study, which has the additional 
aim of assessing the effect of MI in preventing medication errors [39]. Therefore,
“medication errors” was another principal end-point variable and was used to 
calculate the sample size of the study. For a one-tailed test, an alpha error of 5% and 
a power of 80%, based on the results obtained by Fern ndez-Lisón [40] (average 
medication errors per patient: 1.8 and 1 SD), we expect to find an average of 1.0 
medication errors in the EG and 1.6 in the CG. For 1.0 SD and 15% losses, the minimum
number of patients to be studied would be 46 per group. Estimates of the intracluster 
correlation coefficient in cluster randomized trials in primary care are generally less 
than 0.05 [40]. These intracluster correlation coefficients are translated to a cluster 
size of 15 on a design eff ct that corresponds to a factor of 1.7. Therefore, the 
predetermined sample size was 78 patients in each group (46 × 1.7 = 78, that is, 156 
patients). Because the main outcome variable of the present study is MA, and 
considering our previous results [39], with this sample size a difference of 10% in MA 
between both groups could be detected (alpha error=5%, beta error=20%, unilateral 
hypothesis).














2.7 Statistical Analysis 
The Student’s t-test and chi-squared test were used for analyzing differences between 
groups at baseline. McNemar’s test was applied for assessing adherence. Absolute Risk 
Reduction (ARR = %MA in the EG – %MA in CG), Relative Risk Reduction (RRR = %MA in 
EG/%MA in CG) and Number Needed to Treat (NNT=1/ARR) were also calculated (95%
confidence interval (CI)). To control for a cluster effect, a multilevel logistic regression 
was performed, considering the presence or absence of patient MA at the end of the 
study as a dependent variable. The independent variables in the maximum model 
were: group, profession, age, gender, marital status, educational level, social class, 
family situation, type of clinical care received in the last year, number of chronic health 
problems, quality of life, amount of medication, and electronic prescription use. The 
MLwiN software package (Centre for Multilevel Modelling, Bristol, UK) was used. The 
study was approved by the Clinical Research Ethics Committee of Reina Sofia Hospital
in Córdoba, Spain. 
3. Results
3.1 Baseline Characteristics
This study began with 154 patients (70 in the EG and 84 in CG) and ended with147
patients (66 in EG and 81 in CG) (Fig. 1). There were five losses (3/2 EG/CG) because 
they did not include any patient. There were 27 participating researchers (16 
physicians and 11 nurses) in both groups: 11 males (4/7 EG/CG) and 16 females (8/8 
EG/CG). None of the patients who were invited to participate refused to be included 
in the study.














Average participant age was 76 years, and 68.8% were women. The two groups were 
comparable at baseline and there were no significant differences in any of the 
prognostic variables (Table 1). There was no significant difference between the groups 
regarding the number of medications taken at the first visit, medications stored at 
home, number of prescription or nonprescription medications, brand name or generic
medication, and repeat or expired medication.
3.2 Proportional Change in Adherence Category
Figure 2 shows the percentage of patients classified as adherent in both groups at 
baseline and at the end of the study. The proportion of subjects changing to adherence 
in the EG was 24.3%, whereas it was 16.7% in the CG, i.e., 7.6% higher in the EG 
(McNemar’s test; p<0.001). 
3.3 Factors Related to Medication Adherence
Using multivariable analysis (Table 2) and after adjusting for other independent 
variables, those related to medication adherence were the following: motivational 
intervention (OR=2.57; 95% CI: 1.12–5.90), female patient (OR=0.16; 95% CI: 0.05–
0.51), and high level of education (OR=5.68; 95% CI: 1.38–23.41). Other results were: 
ARR: 15.6% (95% CI: 1.0–32%), RRR: 1.54 (95% CI: 0.99–2.40), and NNT: 7 (95% CI: 4–
20.6). 
4. Discussion and Conclusion
4.1 Discussion
4.1.1 Main findings
In this study, MI showed a significant effect on improvement of MA in comparison 
with the usual intervention of providing patient information and advice. Providers who 














used a motivational strategy achieved an MA that was considered relevant to 
predetermined criteria (> 80% and <110%) and that was 7.6% higher than for 
providers those who did not use this strategy. Furthermore, MI was one of the three 
variables (together with being female and having a high educational level) that were
independently associated with MA. The effectiveness of the intervention was not 
related to the type of provider.
4.1.2 Interpretation of findings and comparison with existing literature
In this study, both groups of participants, those undergoing MI intervention and those 
receiving more traditional intervention, significantly increased their adherence to 
treatment during the follow-up period. This result showed the efficacy of both 
interventions; however, MI helped patients to further improve treatment adherence 
and to achieve a level of adherence considered relevant from a clinical standpoint 
[1,37,38], compared with a communicative approach based on only offering advice 
and information. Traditional MI has been mainly used in the treatment of various 
lifestyle problems and diseases, psychological as well as physiological. In the field of 
behavioral change, controversy still exists about the usefulness of advice and 
education in contrast to more (intensive) patient-centered approaches such as MI 
[21,41]. The findings of this study provide evidence to support the usefulness of both 
approaches in promoting medication adherence in elderly patients who are being 
treated by polypharmacy. However, the study also shows the advantages of a 
motivational strategy over a traditional one, and adds to other previous studies in the 
area of adherence, using more carefully selected populations and health problems 
[42–44]. 














In a primary care practice context, the practicability of any strategy is an important 
issue, and this is particularly true with respect to the application of MI counselling 
methods used to support the adherence efforts of patients taking medication [45]. This 
issue is closely related to other factors such as the provider, setting, timing of the 
intervention, and the number of sessions needed or duration of the effects. With 
respect to these practicability issues, our program characteristics (different providers, 
the number of visits, period between visits and duration of each visit) are in line with 
recommendations of the Spanish Primary Care Preventive Program (PAPPS) [47] and 
other Spanish regional health care programs [48]. Based on existing literature [41], one 
type of primary care practitioner (e.g., a physician) does not seem to be better 
equipped than another (e.g., a nurse) to provide face-to-face communication related 
to behavior change techniques. In our study, physicians and nurses were both trained 
in MI skills and delivered the intervention, providing evidence for the value of 
incorporating the MI communication style into clinical nursing practice, as other 
studies have also shown [44,48]. This is particularly important in a primary health care 
system, where the role of nurses is to a great extent, involved with the monitoring and 
follow-up of patients with chronic diseases. Thus, we consider the improvement in the 
main outcome as relevant not only because this kind of interventions are feasible in 
our setting (home visit programs) but also because they introduce a more respectful 
and patient-centered provider-patient relationship model. Although our motivational 
approach should be considered holistically, the role of some specific features stressed 
in our intervention can be highlighted here, particularly the specific evaluation of 
patient ambivalence and exploration of patient ideas and concerns about their lack of 
adherence, so as to apply specific interviewing skills. Carrying out any of these 














approaches specifically may be more feasible in a primary care context. Further 
research is needed to investigate the potential effect of these different interventions 
on MA in comparison with providing advice or information. 
The percentage for participant lack of adherence recorded in this study was higher 
than that reported in other studies of polypharmacy in elderly patients. This low 
pattern of adherence at baseline could be owing to the fact that participants were 
chosen depending on their lack of adherence and the method used to identify this lack 
of adherence in the study (e.g., counting patients’ pills). At the end of the period, 
participants in the EG increased their treatment adherence 24.3% whereas those in
the CG increased 16.7%. Direct comparisons with other studies are difficult because of 
the varying time periods used to calculate adherence r tes, the methods used to 
measure these rates and the type of patients and their health problems. Nevertheless, 
these figures can be considered comparable to those of other studies [44, 49]. 
Finally, the success probability of MI interventions increases with the number of 
patient encounters, and a longer follow-up period increases the percentage of studies 
showing a positive effect. Ruback et al. [21] found this effect in 36% of studies with 3
months of follow-up, wh reas this effect was found in 81% of studies with a follow-up 
period of 12 months or more, for any type of intervention. Our study found 
interventions effective with a follow-up period of 6 months, so we can assume that our 
program could have produced even better adherence rates with a longer follow-up 
period.














4.1.2 Strengths and limitations of the study
Our study has some limitations that should be noted. In line with what has been 
proposed by other authors (1,36,37), here we used a criterion of between 80% and 
110% to define compliance as clinically significant. We consider this appropriate for 
the type of patients studied, the context of care in which the intervention was 
delivered and the characteristics of the intervention itself. However, it is certainly a 
subjective criterion, which may be considered inappropriate under different 
circumstances. This also represents a limitation in evaluating the real effectiveness 
of our intervention.
It was not possible to mask the intervention, either to patients or providers. This 
influences the performance and responsiveness of patients. Providers who chose to 
participate in the study may have had greater motivation for the study than those who 
declined. It is also possible that the CG providers conducted a more intensive 
intervention than usual (i.e., they might have been more friendly or pleasant with 
good performers and therefore more likely to improve patient compliance). 
Participants were recruited by consecutive sampling from among patients who had 
medical consultations for any reason, so we can assume that they were
representative of the population that regularly attends primary care centers that 
also met the inclusion criteria. The multicentric nature of the study gives greater 
external validity to the results. Obviously, the study could not be blind. Furthermore, 
we assume observer bias (Hawthorne effect), implicit in the behavior they may 
adopt when they are invited to participate in a clinical trial. However this is not a 
differential bias here, since patients in both the experimental and control groups 
received an intervention














On the other hand, some studies have shown that the very act of counting pills itself 
implies an increase in compliance that could mask any real effect. In any case, these 
factors could have produced a conservative effect on the results.
4.2 Conclusion
To promote adherence to treatments in elderly chronic patients who are being 
treated by polypharmacy, primary care physicians and nurses can effectively use
both traditional informative and advice strategies and motivational approaches. 
Although MI seems to contribute more to acquiring levels of adherence considered 
relevant, more research is needed to establish the efficacy of this counselling 
approach.
4.3 Practice Implications
Motivational interviewing is a patient-centered method that can be used by physicians 
and nurses to improve medication adherence in primary care.
Figure Legends
Figure 1. CONSORT flow diagram
Figure 2. Percentage of adherence to medication (> 80% and <110%) in both groups at 
baseline and at the end of follow-up
Acknowledgments
This study was supported by the Spanish Society of Family and Community Medicine 
(semFYC) and Andalusian Society of Family and Community Medicine "Isabel 
Fernández" research grant, and the Ministry of Health of the Government of 
Andalusia, Spain (PI-0101/2008).














Conflict of interest 
The authors have no conflict of interest to declare.
References
1. Haynes RB, Taylor DW, Sackett DL: Compliance in health care. Baltimore: Johns 
Hopkins University Press; 1979.
2. World Health Organization: Adherence to long-term therapies. Evidences for action. 
Geneva: WHO; 2003.
3. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW: Patient adherence and 
medical treatment outcomes: a meta-analysis. Med Care 2002;40:794- 811.
4. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS: Impact of medication 
adherence on hospitalization risk and healthcare cost. Med Care 2005, 43:521- 30.
5. Kravitz RL, Melnikow J: Medical adherence research: time for a change in 
direction?. Med Care 2004;42:197-9.
6. Simon, SR, Chan KA, Soumerai SB, Wagner AK, Andrade SE, Feldstein AC, et al: 
Potentially inappropriate medication use by elderly persons in U.S. health 
maintenance organizations, 2000–2001. J Am Geriatr Soc 2005;53:227-32.
7. Fulton MM, Allen ER: Polypharmacy in the elderly: A literature review. J Am Acad 
Nurse Pract 2005;17:123-7.
8. Simpson SH, Eurico DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al: A meta-
analysis of the association between adherence to drug therapy and mortality. BMJ 
2006;33:15-20.














9. McDonald HP, Garg AX, Haynes RB: Interventions to enhance patient adherence 
to medication prescriptions: scientific review. JAMA 2002;288:2868-79.
10. Peterson AM, Takiya L, Finley R. Meta-analysis of trials of interventions to 
improve medication adherence. Am J Health Syst Pharm 2003;60:657-5.
11. Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, 
Svarstad B: Effectiveness of interventions to improve patient compliance: a meta-
analysis. Med Care 1998;36:1138-61.
12. Krueger KP, Felkey BG, Berger BA: Improving adherence and persistence: a 
review and assessment of interventions and description of steps toward a national 
adherence initiative. J Am Pharm Assoc 2003;43:668-78.
13. Haynes RB, Yao X, Degani A, Kripalani S, Garg A, 
McDonald HP: Interventions to enhance medication adherence. Cochrane 
Database Syst Rev 2005; (4) CD000011.
14. Schroeder K, Fahey T, Ebrahim S: How Can We Improve Adherence to blood 
pressure–lowering medication in ambulatory care?. Systematic review of 
randomized controlled trials. Arch Intern Med 2004;164:722-32.
15. Sabate E: Adherence Meeting Report. Geneva: WHO; 2001.
16. Morisky DE, Green LE, Levine AM: Concurrent and predictor validity of selfreported 
measure of medication adherence. Med Care 1986;1:67–74.
17. Adherence to long-term therapies: evidence for action. Geneve: WHO; 2003.
18. Zolnierek CB, DiMatteo MR: Physician Communication and Patient Adherence to 
Treatment: A Meta-analysis. Med Care 2009;47:826-34.














19. Rollnick S, Miller WR, Butler CC: Motivational Interviewing: Principles and Evidence 
in Motivational Interviewing in Health Care: Helping Patients Change Behavior. 
New York: Gilford Press; 2008.
20. Burke BL: The efficacy of Motivational Interviewing and Its Adaptations: What We 
Know So Far. In Motivational Interviewing: Preparing People for Change, Volume 2. 
Edited by Miller WR, Rollnick S. New York: Guilford Press; 2002.
21. Rubak S, Sandbæk A, Lauritzen T, Christensen B: Motivational interviewing: a 
systematic review and meta-analysis. Br J Gen Pract 2005;55:305-12.
22. Lundahl B, Burke BL: The effectiveness and applicability of motivational 
interviewing: a practice-friendly review of four meta-analyses. J Clin Psychol 
2009;65:1232-45.
23. Burke BL, Dunn CW, Atkins DC, Phelps JS: The emerging evidence base for 
motivational interviewing: A meta-analytic and qualitative inquiry. Journal Cognit 
Psychother 2004;18:309-22.
24. Bóveda Fontán J, Pérula de Torres LA, Campíñez Navarro M, Bosch Fontcuberta JM, 
Barragán Brun N, Prados Castillejo JA. [Current evidence on the motivational 
interview in the approach to health care problems in primary care]. Aten Primaria 
2013;45:486-95.
25. Campbell MK, Piaggio G, Elbourne DR, Altman DG; for the CONSORT Group: 
Consort 2010 statement: extension to cluster randomised trials. BMJ 
2012;345:e5661.
26. [Portfolio of Services in Primary Care]. Sevilla: Servicio Andaluz de Salud. Dirección 
General de Asistencia Sanitaria. Subdirección de Programas y desarrollo, 2003. 
















27. Rodríguez Chamorro MA, García-Jiménez E, Amariles P, Rodríguez Chamorro A, 
Faus MJ. [Review of the test used for measuring therapeutic compliance in clinical 
practice]. Aten Primaria. 2008; 40: 413-8.
28. Val A, Amorós G, Martínez P, Fernández Ferré ML, León Sanromà M: [Descriptive 
study of adherence to antihypertensive drug treatment and Morisky-Green test 
validation]. Aten Primaria 1992;10:767–70.
29. Mahoney FI, Barthel D: Functional evaluation: The Barthel Index. Maryland State 
Medical Journal 1965;14:56-61.
30. Martínez de la Iglesia J, Dueñas Herrero R, Onis Vilches MC, Dueñas Herrero R, 
Albert Colomer C, Aguado Taberné C, et al. [Spanish adaptation and validation of 
the Pfeiffer questionnaire (SPMSQ) to detect the presence of cognitive impairment 
in people over 65]. Med Clin (Barc) 2001;117:129-34.
31. Gavilán E, Pérula de Torres LA, Ruiz Moral R. [Assessing clinical patient-centered 
approach: Analysis of the psychometric properties of CICAA scale]. Aten Primaria 
2010; 42:162-8.
32. Pérula LA, Campíñez M, Bosch JM, Barragán N, Arboníes JC, Bóveda J, et al. 
Validation of a Scale for Measuring Motivational Interviewing Skills in Primary Care: 
EVEM Study Protocol. BMC Family Practice 2012;13:112.
33. [Pamphlet ISMP-OCU saftely How to use drugs ("How to use your medicine 
safely")].http://www.ismp-espana.org/ficheros/ocu.pdf.














34. WHO. International Classification of Diseases, 9th revision. 
http://eciemaps.mspsi.es/ecieMaps-
2010/basic_search/cie9mc_basic_search.html.
35. WHO. Collaborating Centre for Drug Statistics Methodology. Anatomical 
Therapeutic Chemical (ATC) Classification Index including Defined Daily Doses 
(DDDs) for Plain Substances. http://www.whocc.no/atcddd/. 
36. Lizán L, Reig A: [Cross-cultural adaptation of a measure of quality of life related to 
health: the Spanish version of COOP/WONCA vigentes]. Aten Primaria 1999;24:75-
82. 
37. Rodríguez Chamorro MA, García-Jiménez E, Amariles P, Rodríguez Chamorro A, 
Faus MJ. [Review of the test used for measuring therapeutic compliance in clinical 
practice]. Aten Primaria. 2008; 40: 413-8.
38. Márquez Contreras E , Casado Martínez JJ, Motero Carrasco J, Martín de Pablosa JL, 
Chaves Gonzáleza R, Losada Ruiz C, et al: [Therapeutic compliance in dyslipidemias 
measured by electronic monitors. How effective is a reminder calendar to avoid 
forgetting?]. Aten Primaria 2007;39:639-47.
39. Pérula de Torres LA, Pulido Ortega L, Pérula de Torres C, González Lama J, Olaya 
Caro I, Ruiz Moral R: [Efficacy of motivational interviewing for reducing medication 
errors in chronic patients over 65 years with polypharmacy: Results of a cluster 
randomized trial]. Med Clin (Barc) 2014;143. doi: 10.1016/j.medcli.2013.07.032.
40. Fernández LC, Barón B, Vázquez B, Martínez T, Prendes JJ, Pujol E: [Medication 
errors and failure therapy in elderly with polypharmacy]. Farm Hosp (Madrid) 
2006;30:2803.














41. Campbell NC, Grimshaw J, Steen N. Sample Size Calculations for Cluster 
Randomised Trials. J Health Serv Res Policy 2000;5:12-6.
42. Noordman J, van der Weijden T, van Dulmen S: Communication-related behavior 
change techniques used in face-to-face lifestyle interventions in primary care: A 
systematic review of the literature. Pat Edu Couns 2012;89:227-44.
43. Brown JM, Miller WR: Impact of motivational interviewing on participation and 
outcome in residential alcoholism treatment. Psychol. Addict. Behav 1993;7:211–
18.
44. Daley DC, Salloum IM, Suckoff A, Kirisci L, Thase ME: Increasing treatment 
adherence among outpatients with depression and cocaine dependence: results of 
a pilot study. Am J Psychiatry 1998;155:1611–3.
45. DiIorio C, McCarty F, Resnicow K, McDonnell Holstad M, Soet J, Yeager K, et al: 
Using motivational interviewing to promote adherence to antiretroviral 
medications: A randomized controlled study. AIDS Care 2008;20:273–83.
46. Lundahl B, Burke BL: The effectiveness and applicability of motivational 
interviewing: a practice-friendly review of four meta-analyses. J Clin Psychol 
2009;65:1232-45.
47. Luque A, del Canto AM, Gorroñogoitia A, Martín I, López-Torres JD, Baena JM: 
[Preventive activities in older]. semFYC: Update PAPPS. 
http://www.papps.org/upload/file/03%20PAPPS%20ACTUALIZACION%202009.pdf.
48. Bueno Dorado T, Carazo García M, Cruz Martos: [Polymedicated Elder Care 
Program]. Consejería de Salud de la Comunidad de Madrid. Madrid: Dirección 
General de Farmacia y Productos Sanitarios Consejería de Sanidad y Consumo; 




















49. Harold E Shinitzky  H, Kub J:  The Art of Motivating Behavior Change: The Use of 
Motivational Interviewing to Promote Health Public Health. Nursing 2001;18:178-
85.
50. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al: A comparison study 
of multiple measures of adherence to HIV protease inhibitors. Ann Intern 
Med 2001;134:968-77.



















(n= 84) P value
Sociodemographics:
-Age: Mean (SD) 75.6 (5.9) 76.1 (5.8) 0.712
-Gender: Number (%) 
    Females 






-Marital Status: Number (%)
   Marriage
   Widowed
   Divorced











   Illiterate
   No education
   Primary Studies
   High School












-Family Situation: Number (%)
   Living with children
   Couple
   Living with other relatives
   Living alone (children nearby)
   Living alone (children far away/no kids)














Chronic Diseases: Mean (SD) 4.9 (2.1) 5.1 (2.6) 0.554
Self reported quality of life -COOP-WONCA Index-:  Mean (SD) 27.4 (6.0) 28.8 (5.4) 0.122
Care Related and Medication:
-Type of Visit (last year): Mean (SD)
  Health Centre Visits: 







-Electronic Prescription: Number (%) 65 (92.9) 75 (89.3) 0.443
-Medication consumption at the beginning of the study: Mean (SD) 8.7 (2.5) 9.0 (3.1) 0.576
-Medication Adherence at the beginning of the study: Mean % (SD) 86.05 (16.8) 80.9 (10.0) 0.053
SD: Standard Deviation














Table 2. Analysis of the variables related with Medication Adherence through Logistic 
regression analysis
95% CI for OR
Variables OR Lower Upper
Group (EG vs. CG) 2.57 1.11 5.90
Gender (Male vs. Female) 0.16 0.05 0.50
Education (Yes vs. No) 5.67 1.37 23.41
EG: Experimental Group; CG: Control Group; OR: Odds Ratio; 95%CI: 95% Confidence Interval; Outcome 
(dependent variable): Medication adherence (yes vs. non). Independent variables considered in the 
model up and ruled out for lacking statistical significance: Provider (doctor vs. nurse), age, marital 
status, family situation (single vs. accompanied), electronic prescription, health centre visits, home 
visits, health chronics problems, amount of medication at the end of the study, medication adherence at 
baseline, self reported quality of life (COOP-WONCA). N=154; Hosmer & Lemeshow test=0.840.














Figure 1. Flow chart CONSORT
32 health providers 
working in  16 health centres 
(8 rural/8 urban) 
n=83 
 withdrawals at this stage: 1 
(significant worsening of functional 
capacity)
 Losses in this phase: 0
 14 health providers (8 doctors and 
6 nurses)
 Losses 2 (1 doctor and 1 nurse)
n=68
 withdrawals at this stage: 1 
(serious disease)
 Losses in this phase: 1 (patient 
resigned to continue in the study)
 13 health providers (8 doctors and 
5 nurses)
 Losses: 3 (2 doctors and 1 nurse)
baseline visit 
(V0)





 withdrawals at this stage: 0
 Losses in this phase: 1 (patient 
resigned  to continue in the study)
n=66
 withdrawals at this stage: 0
 Losses in this phase: 2 (1 
deceased &1 patient resign to 








 Losses in this phase: 0
n=70
 Losses in this phase: 0
Randomization by clusters stratified 
by profession (doctor/ nurse)
 Uptaking: consecutive sampling of 
84 patients
 Patient intervention: usual 
approach
 Uptaking: consecutive sampling of 
70 patients
































Basal visit Final visit
Control group Experimental group
Figure 2. Medication adherence (>80% or <110%) in both groups at baseline and at final of follow-
up
